


THOMSON REUTERS INTEGRITY

QUICK GUIDE SERIES: No. 7



HOW TO USE DISEASE BRIEFINGS AS AN INTEGRATED STARTING POINT

Use **Disease Briefings** for a dynamic summary on the current status of and future trends in drug therapy.

This step-by-step guide shows you:

- The range of information available on a specific disease or condition
- How to drill down to a list of candidates associated with a mechanism of action

EXAMPLE SCENARIO: TYPE 2 DIABETES CANDIDATES

A medicinal chemist working in the area of type 2 diabetes wants to identify developmental candidates associated with target SGLT-2.

1. AN OVERVIEW OF DISEASE BRIEFINGS

- Click on **Disease Briefings** from the Home Page or select it from the pull-down menu of **Knowledge Areas** on other pages of *Integrity*.
- The list of available **Disease Briefings** can be displayed by using the quick access links on the left hand side of the search form.
- Click on **Endocrine Disorders** and then **Diabetes** to view this **Disease Briefing**.

Tip:

- The search form can also be used to view the available list of Disease Briefings by clicking Search Value and selecting Disease Briefing before clicking on the Index button to reveal the list of available titles.
- **Disease Briefings** present information in a text-based format accompanied by multimedia images and tables of compounds launched or under development for the disease.

Tip:

- Each **Disease Briefing** is divided into key areas: **Facts about...**, **Diagnosis**, **Prevention**, **Treatment**, **Targets for Intervention**, **Latest Headlines**, and also includes a **Glossary of Terms** and links to further information.
- To navigate through the briefing click **Next** at the bottom of the screen to move through the pages or use the index on the left side of the screen to move straight to your area of interest.

Tip:

- For rapid location of specific terms, click **Print Full Document** tab (located left below the index) then use the browser **Edit and Find** feature. This type of search locates information found in tables as well as in the text.
- You can save a PDF version of the **Disease Briefing** from within the **Print Full Document** view by clicking the printer icon and then selecting a printer such as PDF Writer, Adobe PDF, etc.

Knowledge Areas Quick Search

120 Records in Disease Briefings

Click a specialty below for a list of related Disease Briefings

- ▶ Autoimmune Disorders
- ▶ Bioterrorism
- ▶ Cancer
- ▶ Cardiovascular Disorders
- ▶ Dermatologic Disorders
- ▶ Digestive Diseases
- ▶ Endocrine Disorders
- ▶ Contraception
- ▶ Diabetes
- ▶ Female Infertility
- ▶ Graves' Disease

Advanced Search

Disease Briefings

Select Value ▶

Optional Value ▶

Optional Value ▶

Product

Lead Compounds Under Active De

Select Value ▶

Optional Value ▶

Optional Value ▶

Diabetes

Facts about Diabetes

Diabetes is a multifactorial disease classified by chronic hyperglycemia resulting from defects in insulin secretion, resistance to insulin action, or both. It is characterized by abnormalities in carbohydrate, fat and protein metabolism observed in the diabetic patient are the result of abnormal insulin secretion and/or action (Adgey, E. et al., 2006).

Hyperglycemia (Figure)

Diabetes: Symptoms and Consequences of Marked Hyperglycemia (Figure)

Print Full Document

Next > Last >>



THOMSON REUTERS™

2. GETTING DETAILED RESULTS

- Click the **Treatment** tab in the index on the left. The list displays information on specific mechanisms of action and compounds acting via those mechanisms. A list of currently marketed therapies appears first in the hierarchy of mechanisms. This is then followed by information on mechanisms with compounds in development stages.
- Click on **Modulators of Glucose Uptake** and then **Sodium-Glucose Cotransporter Inhibitors**.
- Within the **Renal Sodium Glucose Cotransporters: Mechanism of Action (Animation)** click on **Enlarge** and then **Play** for an animated diagram demonstrating the mechanism of action.

Tip:

- Click on the **Glossary of Terms** in the index to see a full list of animations.
- The table below the animation shows a list of SGLT inhibitors in development for the treatment of diabetes, including name of drug, organization developing it, and phase.

Tip:

- Click on **See Chemical Structures** below the table to view structures.
- Click on the name of a compound of interest, for example **Dapagliflozin**, to link to the **Drugs & Biologics** knowledge area and view a full **Product Record**, including chemical structure, mechanisms of action, therapeutic groups and development phases.

Tip:

- For further details use the **Related Information** links at the bottom of the **Product Record** to see information such as **Targets & Pathways**, where you will find information on the SGLT2 target and can view a list of all SGLT2 inhibitors under development for type 2 diabetes.

Related Information					
Drugs & Biologics 4	Targets & Pathways 1	Literature 111	Patents 10	Organic Synthesis 1	Experimental Pharmacology 25
Clinical Studies 30	Companies & Research Institutions 2	Disease Briefings 1		Pharmacokinetics/Metabolism 134	

SGLT inhibitors in development for the treatment of diabetes			
Drug Name	Organization	Mechanism of Action	Status
ASP-1941	Astellas Pharma/Kotobuki	SGLT-2 Inhibitors	Phase III
BI-10773	Boehringer Ingelheim	SGLT-2 Inhibitors	Phase III
Canaqliflozin	Johnson & Johnson	SGLT-2 Inhibitors	Phase III
Dapaqliflozin	AstraZeneca/Bristol-Myers Squibb	SGLT-2 Inhibitors	Phase III

[Click here](#) to view other guides in the *Integrity Quick Guide series*.

If you have any questions about using *Integrity* please contact us at: integritysupport@thomsonreuters.com

